ACTON, Mass., August 26, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, ...
Insulet is bringing a splash of color to the diabetes technology market. | Insulet is bringing a splash of color to the ...
Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...
The Omnipod design eliminates the tubing, consolidating the insulin reservoir and a self-inserting cannula into a single pod, less than the size of a deck of cards, which is controlled by a wireless ...
Medical device maker Insulet's new collaboration with Pantone aims to shift sentiment. Here's why it may work.
The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external tubing typically associated with conventional pumps and eliminates the need for ...
Medical Device Network on MSN

Insulet gets artistic with Omnipod Mango Pantone colour creation

Insulet’s chief growth officer said: “colour has the power to differentiate a brand,” with mango orange adorning Omnipod’s ...
Insulet delivered third-quarter revenue growth of 25% in constant currency and pushed up gross margin by 150 basis points after a savvy decision to consolidate all pumps to the Omnipod 5 platform. Why ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Recommended Reading Insulet seeks label expansion of ...
Strapping on an insulin pump may not always feel heroic, but Insulet and Marvel are changing that narrative with a new comic ...
Bengaluru: Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps. Shares of the medical device maker rose about 2.5% to $251 in ...
A widower has called for health boards to halt the use of Omnipod insulin pumps, as he fears one malfunctioned and killed his husband. Paul McNairney, 39, died last month after the Omnipod delivered ...